GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients
Annals of Vascular Surgery · 2025-12 · 121 · 480-491
DOI: 10.1016/j.avsg.2025.08.013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Vascular Surgery, 2025-12. Verfasst von Elonay Yehualashet und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Peripheral Arterial Disease, Diabetes Mellitus, Incretins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The American Diabetes Association recommends the use of glucagon-like-peptide-1 receptor agonists (GLP1-RAs) (e.g., Ozempic) for patients with atherosclerotic cardiovascular disease, including peripheral artery disease. We hypothesized increasing the use of GLP1-RAs would be associated with improved outcomes after bypass. METHODS: Retrospective review of diabetic patients undergoing infrainguinal bypass at a multihospital institution between 2017 and 2024 was conducted, including patient characteristics, operative details, and outcomes. The primary outcome was survival. Secondary outcomes included perioperative complications, major adverse limb events, major adverse cardiovascular events (MACE), and metabolic changes. Kaplan-Meier and Cox regression evaluated outcomes. RESULTS: A total of 322 patients (62.5% male, 78.8% White, median age 68 [61-76] years) underwent 339 bypasses. GLP1-RA use increased from 8.2% to 18.8% during the study period (P = 0.001). Patients on a GLP1-RA (n = 38, 11.2%) were younger (65.5 [57.0-71.0] vs. 69.9 [62.0-77.0] years, P = 0.003) and had a higher body mass index (29.6 [26.9-33.3] vs. 27.2 [23.3-31.1] kg/m2, P < 0.001). Median follow-up was 18 [6-39] months. Improved survival at 2 years was seen among patients on a GLP1-RA (94.7% vs. 71.8%, P = 0.004). On adjusted analysis, GLP1-RA use was associated with reduced mortality (adjusted hazard ratio = 0.09, 95% confidence interval 0.01-0.66, P = 0.02). Freedom from MACE at 2 years was greater among patients on a GLP-1-RA (100% vs. 88.6%, P = 0.046). Freedom from major adverse limb events was similar between groups. CONCLUSION: GLP1-RA use is increasingly common in patients undergoing lower extremity bypass and was associated with significantly improved postoperative survival and freedom from MACE. Further studies are required to confirm reasons for differences in outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
- Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: domenickna2@upmc.edu.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Yehualashet, E., Mazroua, M. S., Narvaez, E., Jarosinski, M. C., Liang, N. L., Madigan, M. C., Chaer, R. A., & Sridharan, N. D. (2025). GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients. Annals of Vascular Surgery, 121, 480-491. https://doi.org/10.1016/j.avsg.2025.08.013
Vancouver
Yehualashet E, Mazroua MS, Narvaez E, Jarosinski MC, Liang NL, Madigan MC, et al. GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients. Annals of Vascular Surgery. 2025;121:480-491. doi:10.1016/j.avsg.2025.08.013
BibTeX
@article{Yehualashet2025,
author = {Yehualashet, Elonay and Mazroua, Muhammad S and Narvaez, Estefania and Jarosinski, Marissa C and Liang, Nathan L and Madigan, Michael C and Chaer, Rabih A and Sridharan, Natalie D},
title = {GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients},
journal = {Annals of Vascular Surgery},
year = {2025},
volume = {121},
pages = {480--491},
doi = {10.1016/j.avsg.2025.08.013}
}
EUVIMED